Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UGL1
UPID:
KDM5B_HUMAN
Alternative names:
Cancer/testis antigen 31; Histone demethylase JARID1B; Jumonji/ARID domain-containing protein 1B; PLU-1; Retinoblastoma-binding protein 2 homolog 1; [histone H3]-trimethyl-L-lysine(4) demethylase 5B
Alternative UPACC:
Q9UGL1; O95811; Q15752; Q9Y3Q5
Background:
Lysine-specific demethylase 5B, known as Histone demethylase JARID1B, plays a pivotal role in histone code by demethylating 'Lys-4' of histone H3. It does not affect H3 'Lys-9' or 'Lys-27', focusing on H3 'Lys-4' in various methylation states. This protein acts as a transcriptional corepressor for FOXG1B and PAX9, influencing gene expression. Additionally, it has a dual role in cancer, promoting breast cancer cell proliferation while potentially suppressing melanoma.
Therapeutic significance:
Given its involvement in Intellectual developmental disorder, autosomal recessive 65, and its dual role in cancer biology, targeting Lysine-specific demethylase 5B offers a promising avenue for therapeutic intervention. Understanding its function could lead to novel strategies for treating intellectual disabilities and cancer.